Montelukast Sodium Market Size, Share and Growth Outlook 2026: By Product Form (Amorphous / Form-less Montelukast, Crystalline Montelukast), By Dosage Form, By Therapeutic Application, By Distribution Channel, Companies to 2034.
The global Montelukast Sodium Market size is forecast to increase from $546.19 Million in 2026 to $1504.22 Million in 2034 at a CAGR of 13.5% between 2026 and 2034.
The Montelukast Sodium market report provides detailed analysis and outlook of Montelukast Sodium segments including By Product Form (Amorphous / Form-less Montelukast, Crystalline Montelukast), By Dosage Form (Conventional Film-Coated Tablets, Chewable and Fast-Dissolving / Dispersible Tablets, Oral Solutions, Syrups, and Liquids, Oral Granules), By Therapeutic Application (Asthma Management, Allergic Rhinitis, Exercise-Induced Bronchoconstriction (EIB), Urticaria and Chronic Hives), By Distribution Channel (Retail Pharmacies and Drugstores, Hospital Pharmacies, Online Pharmacies and E-commerce Platforms) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.
Montelukast Sodium Industry Overview
Evolving Treatment Guidelines Are Reshaping the Montelukast Sodium Market
The montelukast sodium industry is experiencing significant transition as evolving clinical guidelines, regulatory oversight, and changing prescribing practices influence demand patterns across respiratory care markets. Montelukast sodium has long been utilized for asthma management and allergic rhinitis treatment, but increasing emphasis on benefit-risk assessment and neuropsychiatric safety considerations has prompted healthcare providers to reassess treatment positioning within respiratory care pathways. Pharmaceutical manufacturers are adapting commercial strategies, production planning, and portfolio management decisions in response to shifting utilization trends. At the same time, generic drug suppliers continue to play an increasingly important role in maintaining supply continuity across global healthcare systems.
Regulatory and Clinical Practice Changes Influence Commercial Dynamics
Recent industry developments highlight the impact of revised treatment recommendations on market performance. Organon reported that its Established Brands respiratory portfolio experienced pressure due in part to declining utilization of Singulair® (montelukast sodium) as updated clinical guidelines increasingly prioritize alternative frontline therapies. Healthcare providers are adopting more selective prescribing approaches based on evolving safety evaluations and changing treatment standards. These developments are contributing to adjustments in commercial strategies among branded manufacturers while influencing purchasing patterns across healthcare systems and pharmacy channels.
Generic Manufacturers Strengthen Supply Networks Amid Market Realignment
The industry's competitive landscape is increasingly characterized by supply chain adaptation and growing generic participation. Organon proceeded with the discontinuation of selected Singulair® tablet and chewable tablet product lines following changing commercial conditions and long-term market evaluations. The resulting market adjustments prompted major generic manufacturers including Accord Healthcare, Viatris, and Arrotex Pharmaceuticals to realign production operations for 5 mg and 10 mg montelukast sodium formulations. Temporary capacity constraints emerged in certain Asia-Pacific and European markets as manufacturers responded to increased demand generated by the withdrawal of several branded product offerings. Through revised batch allocation strategies and production optimization initiatives, suppliers have worked to stabilize distribution channels and maintain product availability. These developments illustrate the industry's transition toward a more generic-focused supply structure shaped by regulatory oversight, evolving treatment preferences, and changing respiratory care practices.
Montelukast Sodium Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities
The global Montelukast Sodium market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Cipla Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Lupin Ltd., Glenmark Pharmaceuticals Ltd., Apotex Inc., Viatris Inc.. The Montelukast Sodium market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Montelukast Sodium industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-
Leading companies in Montelukast Sodium industry include- Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Cipla Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Lupin Ltd., Glenmark Pharmaceuticals Ltd., Apotex Inc., Viatris Inc.. The Montelukast Sodium market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.
What to expect in US Montelukast Sodium Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034
The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Montelukast Sodium market remains one of the strongest-performing segments in the country.
The US Montelukast Sodium Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Montelukast Sodium market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Montelukast Sodium industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.
Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Montelukast Sodium markets
Canada's strong Montelukast Sodium sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Montelukast Sodium market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.
Germany Montelukast Sodium Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.
Germany continues to remain the largest Montelukast Sodium market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Montelukast Sodium population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Montelukast Sodium industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Montelukast Sodium market outlook.
France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Montelukast Sodium sales through 2034
France Montelukast Sodium companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.
UK Montelukast Sodium Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain
Small high-need consumer segments remain key priority of Montelukast Sodium distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.
China Montelukast Sodium Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years
China Montelukast Sodium market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Montelukast Sodium industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Montelukast Sodium industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.
India Montelukast Sodium Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India
Indian Montelukast Sodium market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.
Brazil Montelukast Sodium market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities
Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.
Middle East and Africa Montelukast Sodium Industry Trends and Perspectives to 2034
According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.
Montelukast Sodium Market Segmentation
By Product Form
Amorphous / Form-less Montelukast
Crystalline Montelukast
By Dosage Form
Conventional Film-Coated Tablets
Chewable and Fast-Dissolving / Dispersible Tablets
Oral Solutions, Syrups, and Liquids
Oral Granules
By Therapeutic Application
Asthma Management
Allergic Rhinitis
Exercise-Induced Bronchoconstriction (EIB)
Urticaria and Chronic Hives
By Distribution Channel
Retail Pharmacies and Drugstores
Hospital Pharmacies
Online Pharmacies and E-commerce Platforms
Leading Companies in Montelukast Sodium Industry (2026)
Merck & Co., Inc.
Teva Pharmaceutical Industries Ltd.
Aurobindo Pharma Ltd.
Cipla Inc.
Sun Pharmaceutical Industries Ltd.
Dr. Reddy’s Laboratories Ltd.
Lupin Ltd.
Glenmark Pharmaceuticals Ltd.
Apotex Inc.
Viatris Inc.
Countries Included
The Montelukast Sodium market report provides detailed analysis and outlook of Montelukast Sodium segments including By Product Form (Amorphous / Form-less Montelukast, Crystalline Montelukast), By Dosage Form (Conventional Film-Coated Tablets, Chewable and Fast-Dissolving / Dispersible Tablets, Oral Solutions, Syrups, and Liquids, Oral Granules), By Therapeutic Application (Asthma Management, Allergic Rhinitis, Exercise-Induced Bronchoconstriction (EIB), Urticaria and Chronic Hives), By Distribution Channel (Retail Pharmacies and Drugstores, Hospital Pharmacies, Online Pharmacies and E-commerce Platforms) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.
Montelukast Sodium Industry Overview
Evolving Treatment Guidelines Are Reshaping the Montelukast Sodium Market
The montelukast sodium industry is experiencing significant transition as evolving clinical guidelines, regulatory oversight, and changing prescribing practices influence demand patterns across respiratory care markets. Montelukast sodium has long been utilized for asthma management and allergic rhinitis treatment, but increasing emphasis on benefit-risk assessment and neuropsychiatric safety considerations has prompted healthcare providers to reassess treatment positioning within respiratory care pathways. Pharmaceutical manufacturers are adapting commercial strategies, production planning, and portfolio management decisions in response to shifting utilization trends. At the same time, generic drug suppliers continue to play an increasingly important role in maintaining supply continuity across global healthcare systems.
Regulatory and Clinical Practice Changes Influence Commercial Dynamics
Recent industry developments highlight the impact of revised treatment recommendations on market performance. Organon reported that its Established Brands respiratory portfolio experienced pressure due in part to declining utilization of Singulair® (montelukast sodium) as updated clinical guidelines increasingly prioritize alternative frontline therapies. Healthcare providers are adopting more selective prescribing approaches based on evolving safety evaluations and changing treatment standards. These developments are contributing to adjustments in commercial strategies among branded manufacturers while influencing purchasing patterns across healthcare systems and pharmacy channels.
Generic Manufacturers Strengthen Supply Networks Amid Market Realignment
The industry's competitive landscape is increasingly characterized by supply chain adaptation and growing generic participation. Organon proceeded with the discontinuation of selected Singulair® tablet and chewable tablet product lines following changing commercial conditions and long-term market evaluations. The resulting market adjustments prompted major generic manufacturers including Accord Healthcare, Viatris, and Arrotex Pharmaceuticals to realign production operations for 5 mg and 10 mg montelukast sodium formulations. Temporary capacity constraints emerged in certain Asia-Pacific and European markets as manufacturers responded to increased demand generated by the withdrawal of several branded product offerings. Through revised batch allocation strategies and production optimization initiatives, suppliers have worked to stabilize distribution channels and maintain product availability. These developments illustrate the industry's transition toward a more generic-focused supply structure shaped by regulatory oversight, evolving treatment preferences, and changing respiratory care practices.
Montelukast Sodium Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities
The global Montelukast Sodium market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Cipla Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Lupin Ltd., Glenmark Pharmaceuticals Ltd., Apotex Inc., Viatris Inc.. The Montelukast Sodium market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Montelukast Sodium industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-
- Growth Montelukast Sodium Market size outlook across 3 scenarios- High growth, reference, and Low growth cases
- Market Trends, Drivers, Potential Opportunities, and Challenges faced by Montelukast Sodium companies
- Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry
- Detailed SWOT Analysis of global and regional Montelukast Sodium markets
- Competitive analysis including business description, product analysis, and financial profiles
- Key country specific analysis detailing key factors shaping the short-term and long-term outlook
- Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements
Leading companies in Montelukast Sodium industry include- Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Cipla Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Lupin Ltd., Glenmark Pharmaceuticals Ltd., Apotex Inc., Viatris Inc.. The Montelukast Sodium market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.
What to expect in US Montelukast Sodium Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034
The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Montelukast Sodium market remains one of the strongest-performing segments in the country.
The US Montelukast Sodium Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Montelukast Sodium market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Montelukast Sodium industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.
Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Montelukast Sodium markets
Canada's strong Montelukast Sodium sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Montelukast Sodium market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.
Germany Montelukast Sodium Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.
Germany continues to remain the largest Montelukast Sodium market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Montelukast Sodium population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Montelukast Sodium industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Montelukast Sodium market outlook.
France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Montelukast Sodium sales through 2034
France Montelukast Sodium companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.
UK Montelukast Sodium Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain
Small high-need consumer segments remain key priority of Montelukast Sodium distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.
China Montelukast Sodium Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years
China Montelukast Sodium market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Montelukast Sodium industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Montelukast Sodium industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.
India Montelukast Sodium Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India
Indian Montelukast Sodium market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.
Brazil Montelukast Sodium market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities
Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.
Middle East and Africa Montelukast Sodium Industry Trends and Perspectives to 2034
According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.
Montelukast Sodium Market Segmentation
By Product Form
Amorphous / Form-less Montelukast
Crystalline Montelukast
By Dosage Form
Conventional Film-Coated Tablets
Chewable and Fast-Dissolving / Dispersible Tablets
Oral Solutions, Syrups, and Liquids
Oral Granules
By Therapeutic Application
Asthma Management
Allergic Rhinitis
Exercise-Induced Bronchoconstriction (EIB)
Urticaria and Chronic Hives
By Distribution Channel
Retail Pharmacies and Drugstores
Hospital Pharmacies
Online Pharmacies and E-commerce Platforms
Leading Companies in Montelukast Sodium Industry (2026)
Merck & Co., Inc.
Teva Pharmaceutical Industries Ltd.
Aurobindo Pharma Ltd.
Cipla Inc.
Sun Pharmaceutical Industries Ltd.
Dr. Reddy’s Laboratories Ltd.
Lupin Ltd.
Glenmark Pharmaceuticals Ltd.
Apotex Inc.
Viatris Inc.
Countries Included
- North America- US, Canada, Mexico
- Europe- Germany, France, UK, Spain, Italy, Nordics, Others
- Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others
- Latin America- Brazil, Argentina, Others
- Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa
- Get Free print authentication across single, multi, and global licenses
- Free Accompanying excel spreadsheet with complete quantitative data
- Free 2-day consulting support from the lead analyst of the team that developed the report
- Gain clear understanding of current market conditions across 20 countries and plan your decisions accordingly
- Understand competitive profiles of the leading 15 companies in the Electrosurgical Generators industry
- Stay ahead of competition through a detailed analysis of recent market developments
- Make trusted decisions building on our 10-year experience in developing reports on Electrosurgical Generators industry
CHAPTER 1- EXECUTIVE SUMMARY
1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
1.2. Key Industry Highlights, 2026
1.3. Premium Market Insights
1.3.1. Potential Montelukast Sodium Market Types and Applications
1.3.2. Fastest Growing Countries Over the forecast period
1.4. Market Scope and Segmentation
1.4.1. Key Market Segments
1.4.2. Key Countries and Regions
1.4.3. Top Companies in the Montelukast Sodium Industry
1.5. Macroeconomic and Demographic Outlook
1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
1.5.2. Population Forecast by Country, 2010- 2040
1.5.3. Inflation Trends in Leading Countries
1.6. Impact of Trade Policies, Regulations, and Sustainability
1.6.1. Trade tariffs and localization requirements
1.6.2. ESG and sustainability pressures
1.6.3. Compliance-driven structural changes in the value chain
CHAPTER 2- RESEARCH METHODOLOGY
2.1. Report Coverage
2.2. Secondary Research
2.3. Primary Research
2.4. Data Triangulation
2.5. Market Modeling and Forecasting
CHAPTER 3- GLOBAL MONTELUKAST SODIUM MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034
3.1. An Introduction to Global Montelukast Sodium Markets in 2026
3.2. Global Historic and Forecast Montelukast Sodium Market Size Outlook, USD Million, 2021- 2034
3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
3.4. Market Dynamics
3.4.1. Key Montelukast Sodium Market Driving Forces and Their Impact on Market Outlook
3.4.2. Short and Long-Term Trends and Insights Shaping the Future
3.4.3. Potential Montelukast Sodium Market Opportunities for Industry Stakeholders
3.4.4. Potential Challenges across Montelukast Sodium Value Chain
CHAPTER 4- MONTELUKAST SODIUM MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT
4.1. Porter’s Five Forces Analysis
4.1.1. Bargaining Power of Buyers
4.1.2. Bargaining Power of Suppliers
4.1.3. Threat of Substitutes
4.1.4. Threat of New Entrants
4.1.5. Intensity of Competitive Rivalry
4.1.6. Market Attractiveness Analysis by Segment
4.1.7. Market Attractiveness Analysis by Region
4.2. Competitive Landscape
4.2.1 Market Share Analysis of Leading Montelukast Sodium Companies
4.2.2 Recent Strategic Developments
4.2.3 Mergers, Acquisitions, and Partnerships
4.2.4 Product Launches and Innovation Trends
4.2.5 Key Success Factors
4.3. Value Chain Analysis
4.3.1. Key Value Chain Segments
4.3.2. Dominant players by value-chain stage
4.4. SWOT Analysis
4.4.1. Key Strengths and Opportunities
4.4.2. Major Weaknesses and Threats
4.5 Technology Roadmap
4.6 Regulatory and Reimbursement Landscape
CHAPTER 5- MONTELUKAST SODIUM MARKET OUTLOOK BY SEGMENTS
5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034
5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034
5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034
By Product Form
Amorphous / Form-less Montelukast
Crystalline Montelukast
By Dosage Form
Conventional Film-Coated Tablets
Chewable and Fast-Dissolving / Dispersible Tablets
Oral Solutions, Syrups, and Liquids
Oral Granules
By Therapeutic Application
Asthma Management
Allergic Rhinitis
Exercise-Induced Bronchoconstriction (EIB)
Urticaria and Chronic Hives
By Distribution Channel
Retail Pharmacies and Drugstores
Hospital Pharmacies
Online Pharmacies and E-commerce Platforms
CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK
6.1. Base Case Scenario
6.1.1. Definitions and Insights
6.1.2. Market Size Outlook to 2034
6.2. Low Growth Case Scenario
6.2.1. Definitions and Insights
6.2.2. Market Size Outlook to 2034
6.3. High Growth Case Scenario
6.3.1. Definitions and Insights
6.3.2. Market Size Outlook to 2034
CHAPTER 7- NORTH AMERICA MONTELUKAST SODIUM MARKET SIZE ANALYSIS AND OUTLOOK
7.1. North America Montelukast Sodium Market Overview, 2026
7.2. Leading Companies Operating in North America
7.3. Key Industry Statistics, 2026
7.4. North America Montelukast Sodium Market Trends and Growth Opportunities to 2034
7.5. North America Montelukast Sodium Market Size Outlook by Type
7.6. North America Montelukast Sodium Market Size Outlook by Application
7.7. North America Montelukast Sodium Market Size Outlook by Country
7.8. United States
7.8.1. Key Statistics
7.8.2. The US Montelukast Sodium Market Size Outlook, 2021- 2034
7.8.3. Key Market Drivers and Industry Developments in the US Montelukast Sodium Companies
7.9. Canada
7.9.1. Key Statistics
7.9.2. Canada Montelukast Sodium Market Size Outlook, 2021- 2034
7.9.3. Key Market Drivers and Industry Developments in Canada Montelukast Sodium Companies
7.10. Mexico
7.10.1. Key Statistics
7.10.2. Mexico Montelukast Sodium Market Size Outlook, 2021- 2034
7.10.3. Key Market Drivers and Industry Developments in Mexico Montelukast Sodium Companies
CHAPTER 8- EUROPE MONTELUKAST SODIUM MARKET SIZE ANALYSIS AND OUTLOOK
8.1. Europe Montelukast Sodium Market Overview, 2026
8.2. Leading Companies Operating in Europe
8.3. Key Industry Statistics, 2026
8.4. Europe Montelukast Sodium Market Trends and Growth Opportunities to 2034
8.5. Europe Montelukast Sodium Market Size Outlook by Type
8.6. Europe Montelukast Sodium Market Size Outlook by Application
8.7. Europe Montelukast Sodium Market Size Outlook by Country
8.8. Germany
8.8.1. Key Statistics
8.8.2. Germany Montelukast Sodium Market Size Outlook, 2021- 2034
8.8.3. Key Market Drivers and Industry Developments in Germany Montelukast Sodium Companies
8.9. France
8.9.1. Key Statistics
8.9.2. France Montelukast Sodium Market Size Outlook, 2021- 2034
8.9.3. Key Market Drivers and Industry Developments in France Montelukast Sodium Companies
8.10. United Kingdom
8.10.1. Key Statistics
8.10.2. United Kingdom Montelukast Sodium Market Size Outlook, 2021- 2034
8.10.3. Key Market Drivers and Industry Developments in the UK Montelukast Sodium Companies
8.11. Spain
8.11.1. Key Statistics
8.11.2. Spain Montelukast Sodium Market Size Outlook, 2021- 2034
8.11.3. Key Market Drivers and Industry Developments in Spain Montelukast Sodium Companies
8.12. Italy
8.12.1. Key Statistics
8.12.2. Italy Montelukast Sodium Market Size Outlook, 2021- 2034
8.12.3. Key Market Drivers and Industry Developments in Italy Montelukast Sodium Companies
8.13. Rest of Europe
8.13.1. Key Statistics
8.13.2. Rest of Europe Montelukast Sodium Market Size Outlook, 2021- 2034
8.13.3. Key Market Drivers and Industry Developments in Rest of Europe Montelukast Sodium Companies
CHAPTER 9- ASIA PACIFIC MONTELUKAST SODIUM MARKET SIZE ANALYSIS AND OUTLOOK
9.1. Asia Pacific Montelukast Sodium Market Overview, 2026
9.2. Leading Companies Operating in Asia Pacific
9.3. Key Industry Statistics, 2026
9.4. Asia Pacific Montelukast Sodium Market Trends and Growth Opportunities to 2034
9.5. Asia Pacific Montelukast Sodium Market Size Outlook by Type
9.6. Asia Pacific Montelukast Sodium Market Size Outlook by Application
9.7. Asia Pacific Montelukast Sodium Market Size Outlook by Country
9.8. China
9.8.1. Key Statistics
9.8.2. China Montelukast Sodium Market Size Outlook, 2021- 2034
9.8.3. Key Market Drivers and Industry Developments in China Montelukast Sodium Companies
9.9. Japan
9.9.1. Key Statistics
9.9.2. Japan Montelukast Sodium Market Size Outlook, 2021- 2034
9.9.3. Key Market Drivers and Industry Developments in Japan Montelukast Sodium Companies
9.10. India
9.10.1. Key Statistics
9.10.2. India Montelukast Sodium Market Size Outlook, 2021- 2034
9.10.3. Key Market Drivers and Industry Developments in India Montelukast Sodium Companies
9.11. South Korea
9.11.1. Key Statistics
9.11.2. South Korea Montelukast Sodium Market Size Outlook, 2021- 2034
9.11.3. Key Market Drivers and Industry Developments in South Korea Montelukast Sodium Companies
9.12. Australia
9.12.1. Key Statistics
9.12.2. Australia Montelukast Sodium Market Size Outlook, 2021- 2034
9.12.3. Key Market Drivers and Industry Developments in Australia Montelukast Sodium Companies
9.13. Southeast Asia
9.13.1. Key Statistics
9.13.2. Southeast Asia Montelukast Sodium Market Size Outlook, 2021- 2034
9.13.3. Key Market Drivers and Industry Developments in Southeast Asia Montelukast Sodium Companies
CHAPTER 10- SOUTH AND CENTRAL AMERICA MONTELUKAST SODIUM MARKET SIZE ANALYSIS AND OUTLOOK
10.1. South and Central America Montelukast Sodium Market Overview, 2026
10.2. Leading Companies Operating in South and Central America
10.3. Key Industry Statistics, 2026
10.4. South and Central America Montelukast Sodium Market Trends and Growth Opportunities to 2034
10.5. South and Central America Montelukast Sodium Market Size Outlook by Type
10.6. South and Central America Montelukast Sodium Market Size Outlook by Application
10.7. South and Central America Montelukast Sodium Market Size Outlook by Country
10.8. Brazil
10.8.1. Key Statistics
10.8.2. Brazil Montelukast Sodium Market Size Outlook, 2021- 2034
10.8.3. Key Market Drivers and Industry Developments in Brazil Montelukast Sodium Companies
10.9. Argentina
10.9.1. Key Statistics
10.9.2. Argentina Montelukast Sodium Market Size Outlook, 2021- 2034
10.9.3. Key Market Drivers and Industry Developments in Argentina Montelukast Sodium Companies
10.10. Rest of Latin America
10.10.1. Key Statistics
10.10.2. Rest of Latin America Montelukast Sodium Market Size Outlook, 2021- 2034
10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America Montelukast Sodium Companies
CHAPTER 11- MIDDLE EAST AND AFRICA MONTELUKAST SODIUM MARKET SIZE ANALYSIS AND OUTLOOK
11.1. Middle East and Africa Montelukast Sodium Market Overview, 2026
11.2. Leading Companies Operating in Middle East and Africa
11.3. Key Industry Statistics, 2026
11.4. Middle East and Africa Montelukast Sodium Market Trends and Growth Opportunities to 2034
11.5. Middle East and Africa Montelukast Sodium Market Size Outlook by Type
11.6. Middle East and Africa Montelukast Sodium Market Size Outlook by Application
11.7. Middle East and Africa Montelukast Sodium Market Size Outlook by Country
11.8. Saudi Arabia
11.8.1. Key Statistics
11.8.2. Saudi Arabia Montelukast Sodium Market Size Outlook, 2021- 2034
11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia Montelukast Sodium Companies
11.9. United Arab Emirates
11.9.1. Key Statistics
11.9.2. The UAE Montelukast Sodium Market Size Outlook, 2021- 2034
11.9.3. Key Market Drivers and Industry Developments in the UAE Montelukast Sodium Companies
11.10. Africa
11.10.1. Key Statistics
11.10.2. Africa Montelukast Sodium Market Size Outlook, 2021- 2034
11.10.3. Key Market Drivers and Industry Developments in Africa Montelukast Sodium Companies
CHAPTER 12- COMPANY PROFILES
12.1. Top Companies in Montelukast Sodium Industry
Merck & Co., Inc.
Teva Pharmaceutical Industries Ltd.
Aurobindo Pharma Ltd.
Cipla Inc.
Sun Pharmaceutical Industries Ltd.
Dr. Reddy’s Laboratories Ltd.
Lupin Ltd.
Glenmark Pharmaceuticals Ltd.
Apotex Inc.
Viatris Inc.
12.2. Business Description
12.3. SWOT Profiles
12.4. Products and Services
CHAPTER 13- APPENDIX
Glossary of Terms
Research Methodology & Data Sources
Conclusion & Strategic Recommendations
1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
1.2. Key Industry Highlights, 2026
1.3. Premium Market Insights
1.3.1. Potential Montelukast Sodium Market Types and Applications
1.3.2. Fastest Growing Countries Over the forecast period
1.4. Market Scope and Segmentation
1.4.1. Key Market Segments
1.4.2. Key Countries and Regions
1.4.3. Top Companies in the Montelukast Sodium Industry
1.5. Macroeconomic and Demographic Outlook
1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
1.5.2. Population Forecast by Country, 2010- 2040
1.5.3. Inflation Trends in Leading Countries
1.6. Impact of Trade Policies, Regulations, and Sustainability
1.6.1. Trade tariffs and localization requirements
1.6.2. ESG and sustainability pressures
1.6.3. Compliance-driven structural changes in the value chain
CHAPTER 2- RESEARCH METHODOLOGY
2.1. Report Coverage
2.2. Secondary Research
2.3. Primary Research
2.4. Data Triangulation
2.5. Market Modeling and Forecasting
CHAPTER 3- GLOBAL MONTELUKAST SODIUM MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034
3.1. An Introduction to Global Montelukast Sodium Markets in 2026
3.2. Global Historic and Forecast Montelukast Sodium Market Size Outlook, USD Million, 2021- 2034
3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
3.4. Market Dynamics
3.4.1. Key Montelukast Sodium Market Driving Forces and Their Impact on Market Outlook
3.4.2. Short and Long-Term Trends and Insights Shaping the Future
3.4.3. Potential Montelukast Sodium Market Opportunities for Industry Stakeholders
3.4.4. Potential Challenges across Montelukast Sodium Value Chain
CHAPTER 4- MONTELUKAST SODIUM MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT
4.1. Porter’s Five Forces Analysis
4.1.1. Bargaining Power of Buyers
4.1.2. Bargaining Power of Suppliers
4.1.3. Threat of Substitutes
4.1.4. Threat of New Entrants
4.1.5. Intensity of Competitive Rivalry
4.1.6. Market Attractiveness Analysis by Segment
4.1.7. Market Attractiveness Analysis by Region
4.2. Competitive Landscape
4.2.1 Market Share Analysis of Leading Montelukast Sodium Companies
4.2.2 Recent Strategic Developments
4.2.3 Mergers, Acquisitions, and Partnerships
4.2.4 Product Launches and Innovation Trends
4.2.5 Key Success Factors
4.3. Value Chain Analysis
4.3.1. Key Value Chain Segments
4.3.2. Dominant players by value-chain stage
4.4. SWOT Analysis
4.4.1. Key Strengths and Opportunities
4.4.2. Major Weaknesses and Threats
4.5 Technology Roadmap
4.6 Regulatory and Reimbursement Landscape
CHAPTER 5- MONTELUKAST SODIUM MARKET OUTLOOK BY SEGMENTS
5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034
5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034
5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034
By Product Form
Amorphous / Form-less Montelukast
Crystalline Montelukast
By Dosage Form
Conventional Film-Coated Tablets
Chewable and Fast-Dissolving / Dispersible Tablets
Oral Solutions, Syrups, and Liquids
Oral Granules
By Therapeutic Application
Asthma Management
Allergic Rhinitis
Exercise-Induced Bronchoconstriction (EIB)
Urticaria and Chronic Hives
By Distribution Channel
Retail Pharmacies and Drugstores
Hospital Pharmacies
Online Pharmacies and E-commerce Platforms
CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK
6.1. Base Case Scenario
6.1.1. Definitions and Insights
6.1.2. Market Size Outlook to 2034
6.2. Low Growth Case Scenario
6.2.1. Definitions and Insights
6.2.2. Market Size Outlook to 2034
6.3. High Growth Case Scenario
6.3.1. Definitions and Insights
6.3.2. Market Size Outlook to 2034
CHAPTER 7- NORTH AMERICA MONTELUKAST SODIUM MARKET SIZE ANALYSIS AND OUTLOOK
7.1. North America Montelukast Sodium Market Overview, 2026
7.2. Leading Companies Operating in North America
7.3. Key Industry Statistics, 2026
7.4. North America Montelukast Sodium Market Trends and Growth Opportunities to 2034
7.5. North America Montelukast Sodium Market Size Outlook by Type
7.6. North America Montelukast Sodium Market Size Outlook by Application
7.7. North America Montelukast Sodium Market Size Outlook by Country
7.8. United States
7.8.1. Key Statistics
7.8.2. The US Montelukast Sodium Market Size Outlook, 2021- 2034
7.8.3. Key Market Drivers and Industry Developments in the US Montelukast Sodium Companies
7.9. Canada
7.9.1. Key Statistics
7.9.2. Canada Montelukast Sodium Market Size Outlook, 2021- 2034
7.9.3. Key Market Drivers and Industry Developments in Canada Montelukast Sodium Companies
7.10. Mexico
7.10.1. Key Statistics
7.10.2. Mexico Montelukast Sodium Market Size Outlook, 2021- 2034
7.10.3. Key Market Drivers and Industry Developments in Mexico Montelukast Sodium Companies
CHAPTER 8- EUROPE MONTELUKAST SODIUM MARKET SIZE ANALYSIS AND OUTLOOK
8.1. Europe Montelukast Sodium Market Overview, 2026
8.2. Leading Companies Operating in Europe
8.3. Key Industry Statistics, 2026
8.4. Europe Montelukast Sodium Market Trends and Growth Opportunities to 2034
8.5. Europe Montelukast Sodium Market Size Outlook by Type
8.6. Europe Montelukast Sodium Market Size Outlook by Application
8.7. Europe Montelukast Sodium Market Size Outlook by Country
8.8. Germany
8.8.1. Key Statistics
8.8.2. Germany Montelukast Sodium Market Size Outlook, 2021- 2034
8.8.3. Key Market Drivers and Industry Developments in Germany Montelukast Sodium Companies
8.9. France
8.9.1. Key Statistics
8.9.2. France Montelukast Sodium Market Size Outlook, 2021- 2034
8.9.3. Key Market Drivers and Industry Developments in France Montelukast Sodium Companies
8.10. United Kingdom
8.10.1. Key Statistics
8.10.2. United Kingdom Montelukast Sodium Market Size Outlook, 2021- 2034
8.10.3. Key Market Drivers and Industry Developments in the UK Montelukast Sodium Companies
8.11. Spain
8.11.1. Key Statistics
8.11.2. Spain Montelukast Sodium Market Size Outlook, 2021- 2034
8.11.3. Key Market Drivers and Industry Developments in Spain Montelukast Sodium Companies
8.12. Italy
8.12.1. Key Statistics
8.12.2. Italy Montelukast Sodium Market Size Outlook, 2021- 2034
8.12.3. Key Market Drivers and Industry Developments in Italy Montelukast Sodium Companies
8.13. Rest of Europe
8.13.1. Key Statistics
8.13.2. Rest of Europe Montelukast Sodium Market Size Outlook, 2021- 2034
8.13.3. Key Market Drivers and Industry Developments in Rest of Europe Montelukast Sodium Companies
CHAPTER 9- ASIA PACIFIC MONTELUKAST SODIUM MARKET SIZE ANALYSIS AND OUTLOOK
9.1. Asia Pacific Montelukast Sodium Market Overview, 2026
9.2. Leading Companies Operating in Asia Pacific
9.3. Key Industry Statistics, 2026
9.4. Asia Pacific Montelukast Sodium Market Trends and Growth Opportunities to 2034
9.5. Asia Pacific Montelukast Sodium Market Size Outlook by Type
9.6. Asia Pacific Montelukast Sodium Market Size Outlook by Application
9.7. Asia Pacific Montelukast Sodium Market Size Outlook by Country
9.8. China
9.8.1. Key Statistics
9.8.2. China Montelukast Sodium Market Size Outlook, 2021- 2034
9.8.3. Key Market Drivers and Industry Developments in China Montelukast Sodium Companies
9.9. Japan
9.9.1. Key Statistics
9.9.2. Japan Montelukast Sodium Market Size Outlook, 2021- 2034
9.9.3. Key Market Drivers and Industry Developments in Japan Montelukast Sodium Companies
9.10. India
9.10.1. Key Statistics
9.10.2. India Montelukast Sodium Market Size Outlook, 2021- 2034
9.10.3. Key Market Drivers and Industry Developments in India Montelukast Sodium Companies
9.11. South Korea
9.11.1. Key Statistics
9.11.2. South Korea Montelukast Sodium Market Size Outlook, 2021- 2034
9.11.3. Key Market Drivers and Industry Developments in South Korea Montelukast Sodium Companies
9.12. Australia
9.12.1. Key Statistics
9.12.2. Australia Montelukast Sodium Market Size Outlook, 2021- 2034
9.12.3. Key Market Drivers and Industry Developments in Australia Montelukast Sodium Companies
9.13. Southeast Asia
9.13.1. Key Statistics
9.13.2. Southeast Asia Montelukast Sodium Market Size Outlook, 2021- 2034
9.13.3. Key Market Drivers and Industry Developments in Southeast Asia Montelukast Sodium Companies
CHAPTER 10- SOUTH AND CENTRAL AMERICA MONTELUKAST SODIUM MARKET SIZE ANALYSIS AND OUTLOOK
10.1. South and Central America Montelukast Sodium Market Overview, 2026
10.2. Leading Companies Operating in South and Central America
10.3. Key Industry Statistics, 2026
10.4. South and Central America Montelukast Sodium Market Trends and Growth Opportunities to 2034
10.5. South and Central America Montelukast Sodium Market Size Outlook by Type
10.6. South and Central America Montelukast Sodium Market Size Outlook by Application
10.7. South and Central America Montelukast Sodium Market Size Outlook by Country
10.8. Brazil
10.8.1. Key Statistics
10.8.2. Brazil Montelukast Sodium Market Size Outlook, 2021- 2034
10.8.3. Key Market Drivers and Industry Developments in Brazil Montelukast Sodium Companies
10.9. Argentina
10.9.1. Key Statistics
10.9.2. Argentina Montelukast Sodium Market Size Outlook, 2021- 2034
10.9.3. Key Market Drivers and Industry Developments in Argentina Montelukast Sodium Companies
10.10. Rest of Latin America
10.10.1. Key Statistics
10.10.2. Rest of Latin America Montelukast Sodium Market Size Outlook, 2021- 2034
10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America Montelukast Sodium Companies
CHAPTER 11- MIDDLE EAST AND AFRICA MONTELUKAST SODIUM MARKET SIZE ANALYSIS AND OUTLOOK
11.1. Middle East and Africa Montelukast Sodium Market Overview, 2026
11.2. Leading Companies Operating in Middle East and Africa
11.3. Key Industry Statistics, 2026
11.4. Middle East and Africa Montelukast Sodium Market Trends and Growth Opportunities to 2034
11.5. Middle East and Africa Montelukast Sodium Market Size Outlook by Type
11.6. Middle East and Africa Montelukast Sodium Market Size Outlook by Application
11.7. Middle East and Africa Montelukast Sodium Market Size Outlook by Country
11.8. Saudi Arabia
11.8.1. Key Statistics
11.8.2. Saudi Arabia Montelukast Sodium Market Size Outlook, 2021- 2034
11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia Montelukast Sodium Companies
11.9. United Arab Emirates
11.9.1. Key Statistics
11.9.2. The UAE Montelukast Sodium Market Size Outlook, 2021- 2034
11.9.3. Key Market Drivers and Industry Developments in the UAE Montelukast Sodium Companies
11.10. Africa
11.10.1. Key Statistics
11.10.2. Africa Montelukast Sodium Market Size Outlook, 2021- 2034
11.10.3. Key Market Drivers and Industry Developments in Africa Montelukast Sodium Companies
CHAPTER 12- COMPANY PROFILES
12.1. Top Companies in Montelukast Sodium Industry
Merck & Co., Inc.
Teva Pharmaceutical Industries Ltd.
Aurobindo Pharma Ltd.
Cipla Inc.
Sun Pharmaceutical Industries Ltd.
Dr. Reddy’s Laboratories Ltd.
Lupin Ltd.
Glenmark Pharmaceuticals Ltd.
Apotex Inc.
Viatris Inc.
12.2. Business Description
12.3. SWOT Profiles
12.4. Products and Services
CHAPTER 13- APPENDIX
Glossary of Terms
Research Methodology & Data Sources
Conclusion & Strategic Recommendations
